Case Control in Sarcopenia Among Elderly Type 2 Diabetic Patients

Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients

1. Assess sarcopenia prevalence in elderly diabetic patients.
2. Evaluate impact of diabetes and its medications on muscle health.
3. detect effect of sacropenia on quality of life on elderly

Study Overview

• Status: Not yet recruiting
• Conditions: Sarcopenia
• Intervention / Treatment: Diagnostic test: muscle ultrasound

• Study Type: Observational
• Enrollment (Estimated): 100

Contacts and Locations

• Study Contact: Name: eman alaa eldean, master degree; Phone Number: 2+01098614329; Email: emanalaa359@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

1. Inclusion criteria:

   The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)

   ●Able to give informed consent

2. Exclusion criteria:

   • chronic renal disease
   • chronic liver disese
   • Severe cognitive impairment
   • Known neuromuscular diseases affecting mobility
   • malignancy Data of the study will collected over one year duration from 1/2026 _1/2027

Description

1. Inclusion criteria:

   The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)

   ●Able to give informed consent

2. Exclusion criteria:

   • chronic renal disease
   • chronic liver disese
   • Severe cognitive impairment
   • Known neuromuscular diseases affecting mobility
   • malignancy Data of the study will collected over one year duration from 1/2026 _1/2027

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Diabetic Group; Elderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria.	Diagnostic test: muscle ultrasound; Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity
Non-Diabetic Group; Elderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria.	Diagnostic test: muscle ultrasound; Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic	Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters	Within 6 months from the start of recruitment.
Assessment of muscle strength using handgrip dynamometry	Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded.	Within 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of life score using the SarQoL questionnaire.	Quality of life related to sarcopenia will be evaluated using the validated SarQoL questionnaire.	Within 6 months.

Collaborators and Investigators

• Sponsor: Eman Alaa Eldean Mohamed

Publications and helpful links

General Publications

• Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884.

Study record dates

Study Major Dates

• Study Start (Estimated): December 22, 2025
• Primary Completion (Estimated): October 20, 2027
• Study Completion (Estimated): October 20, 2028

Study Registration Dates

• First Submitted: September 23, 2025
• First Submitted That Met QC Criteria: November 20, 2025
• First Posted (Estimated): November 24, 2025

Study Record Updates

• Last Update Posted (Actual): December 19, 2025
• Last Update Submitted That Met QC Criteria: December 18, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Sarcopenia
• Other Study ID Numbers: sarcopenia in elderly diabetic

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes